Cite
de Graaf H, Payne RO, Taylor I, et al. Safety and Immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I First-in-Human Trial. Front Immunol. 2021;12:694759doi: 10.3389/fimmu.2021.694759.
de Graaf, H., Payne, R. O., Taylor, I., Miura, K., Long, C. A., Elias, S. C., Zaric, M., Minassian, A. M., Silk, S. E., Li, L., Poulton, I. D., Baker, M., Draper, S. J., Gbesemete, D., Brendish, N. J., Martins, F., Marini, A., Mekhaiel, D., Edwards, N. J., Roberts, R., Vekemans, J., Moyle, S., Faust, S. N., Berrie, E., Lawrie, A. M., Hill, F., Hill, A. V. S., & Biswas, S. (2021). Safety and Immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I First-in-Human Trial. Frontiers in immunology, 12694759. https://doi.org/10.3389/fimmu.2021.694759
de Graaf, Hans, et al. "Safety and Immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I First-in-Human Trial." Frontiers in immunology vol. 12 (2021): 694759. doi: https://doi.org/10.3389/fimmu.2021.694759
de Graaf H, Payne RO, Taylor I, Miura K, Long CA, Elias SC, Zaric M, Minassian AM, Silk SE, Li L, Poulton ID, Baker M, Draper SJ, Gbesemete D, Brendish NJ, Martins F, Marini A, Mekhaiel D, Edwards NJ, Roberts R, Vekemans J, Moyle S, Faust SN, Berrie E, Lawrie AM, Hill F, Hill AVS, Biswas S. Safety and Immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I First-in-Human Trial. Front Immunol. 2021 Jul 14;12:694759. doi: 10.3389/fimmu.2021.694759. eCollection 2021. PMID: 34335606; PMCID: PMC8318801.
Copy
Download .nbib